RxDoctor Payments Data

Lawrence Perlmutter, MD

Ophthalmology · Albany, NYNPI 1326102039

Payments from drug & device makers

$12,148in general payments, 2019–2025

Across 532 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Astellas Pharma US Inc$1K
  • Bausch & Lomb Americas Inc.$1K
  • Aerie Pharmaceuticals, Inc.$1K
  • AbbVie$991
  • Tarsus Pharmaceuticals, Inc.$620
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$12,141100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,148 in reported general payments places this provider in the 85th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$302,284
Medicare patients
1,309
Services billed
3,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost42$29,780
MieboPerfluorohexyloctane/Pf19$19,261
XiidraLifitegrast16$18,329
Cyclosporine42$16,325
Brimonidine Tartrate34$13,331
Loteprednol Etabonate39$13,153
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol76$10,786
RocklatanNetarsudil Mesylat/Latanoprost14$10,498
Latanoprost594$9,531
RhopressaNetarsudil Mesylate11$7,440
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat293$6,510
ZirganGanciclovir13$6,274
CombiganBrimonidine Tartrate/Timolol11$5,590
SimbrinzaBrinzolamide/Brimonidine Tart13$5,246
Alphagan PBrimonidine Tartrate13$4,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo, Xiidra, Zirgan$1,025$43,86448 claims
AbbVieLumigan, Combigan, Alphagan P$991$40,00866 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$1,019$17,93725 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$514$13,15339 claims
AlconSimbrinza$2,241$5,24613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →